on MIRA Pharmaceuticals (NASDAQ:MIRA)
MIRA Pharmaceuticals' Ketamir-2 Manuscript Accepted for Publication
MIRA Pharmaceuticals announced that its lead drug candidate, Ketamir-2, has been accepted for publication in the journal Frontiers in Pharmacology. Ketamir-2, currently in a Phase 1 trial for neuropathic pain, is highlighted for its pharmacological differentiation from ketamine.
The article details Ketamir-2 as a low-affinity NMDA receptor antagonist with a clean pharmacological profile. Unlike ketamine, it does not interact significantly with other systems such as dopamine or serotonin.
In preclinical models, Ketamir-2 did not induce hyperlocomotion, suggesting a favorable safety profile. It also demonstrated antidepressant and anxiolytic effects in behavioral tests.
The drug proves effective in oral administration, efficiently crossing the blood-brain barrier. MIRA plans to initiate a Phase 2a trial by the end of 2025.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MIRA Pharmaceuticals news